Nanosized ethanol based malleable liposomes of cytarabine to accentuate transdermal delivery: formulation optimization, in vitro skin permeation and in vivo bioavailability

Artificial Cells, Nanomedicine, and Biotechnology
Rakesh RajAlpana Ram

Abstract

Cytarabine is a pyrimidine nucleoside analog used predominantly for acute myeloid leukemia (AML) and also for other indications, including acute lymphocytic leukemia, chronic myelogenous leukemia, and lymphoma by parenteral route due to its low oral bioavailability. Parenteral administration requires constant plasma level, monitoring for its fluctuation and poor patients compliances. Hence the objective of this work is to construct optimized nanosized malleable liposomes of cytarabine to accentuate transdermal delivery of drug to circumvent previously mentioned drawbacks. We also investigated its characteristics and therapeutic efficiency and attempted to systematically explore the penetration enhancing property. Well characterized ethanolic liposomes were also biologically tested for dermatological safety and systemic bioavailability. Ethanolic liposomes were found to be spherical having nanometric size with low polydispersity and high encapsulation efficiency. Skin permeation and deposition studies revealed significant enhancement. In vivo, skin irritation study of developed formulation showed no erythema or scaling vis-à-vis the liposomes. Blood profile of this novel formulation indicated lower lag time with the high amount ...Continue Reading

References

Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Mar 4, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·E TouitouM Eliaz
Dec 7, 2002·Progress in Lipid Research·Joke A BouwstraMaria Ponec
Mar 17, 2004·Advanced Drug Delivery Reviews·Gregor Cevc
Aug 7, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·R Alvarez-RománR H Guy
Jan 16, 2007·International Journal of Pharmaceutics·Mustafa M A ElsayedNawal M Khalafallah
Mar 14, 2007·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Paola MuraAntonio M Rabasco
Apr 25, 2007·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Vaibhav DubeyN K Jain
Jan 30, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·J de LeeuwH A M Neumann
Jan 30, 2010·Clinical Therapeutics·Tadeusz Robak, Agnieszka Wierzbowska
Jul 28, 2011·Experimental Animals·Hiroyuki TakeuchiKenji Sugibayashi
Feb 3, 2012·Archives of Pharmacal Research·Jian-Ping ZhangXin-An Wu
Mar 15, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Donatella PaolinoMassimo Fresta
Jan 1, 2009·Profiles of Drug Substances, Excipients, and Related Methodology·Hussein I El-Subbagh, Abdullah A Al-Badr
Mar 4, 2014·Colloids and Surfaces. B, Biointerfaces·Vineet KumarSudesh Kumar Yadav
May 9, 2015·Artificial Cells, Nanomedicine, and Biotechnology·Abdul AhadMohd Mujeeb
Jul 15, 2015·International Journal of Nanomedicine·Shuo ShenZu-Guang Ye
Nov 21, 2015·Artificial Cells, Nanomedicine, and Biotechnology·Shakeeb AhmedAzka Gull
Jan 5, 2016·Drug Development and Industrial Pharmacy·Shashank JainSenshang Lin
Mar 1, 2016·Artificial Cells, Nanomedicine, and Biotechnology·Abdullah H Alomrani, Mohamed M Badran
Apr 12, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Rakesh RajAlpana Ram
Jul 9, 2016·The Journal of International Medical Research·Dun Ling XiaLi Xin Zhu
Jul 19, 2016·Colloids and Surfaces. B, Biointerfaces·Joana MartoSandra Simões
Nov 12, 2016·International Journal of Pharmaceutics·Yibang ZhangHuaxi Xu
Nov 21, 2016·Journal of Pharmaceutical Sciences·Shashank JainNamrata Vora
May 12, 2017·International Journal of Nanomedicine·Li YangXiaoliang Zhu
Jan 24, 2018·Stem Cells International·Jia Tang, Takashi Saito

❮ Previous
Next ❯

Citations

Feb 5, 2021·Advanced Drug Delivery Reviews·S G AntimisiarisS Mourtas
Jul 28, 2019·Journal of Pharmaceutical Sciences·Monika KauravRavi Shankar Pandey
Jul 22, 2021·Drug Delivery and Translational Research·Zhiyue ZhaoNan Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.